Primary Progressive Aphasia (PPA) Market

1. Primary Progressive Aphasia Market What is the Primary Progressive Aphasia? Primary Progressive Aphasia is a neurological syndrome in which language capabilities become slowly and progressively impaired. Unlike other forms of aphasia that result from stroke or brain injury, Primary Progressive Aphasia is caused by neurodegenerative diseases, such as Alzheimer’s disease or Frontotemporal Lobar Degeneration. Primary Progressive Aphasia results from deterioration of brain tissue important for speech and language. DelveInsight's new launch on "Primary Progressive Aphasia Market report 2030” delivers an in-depth understanding of the Primary Progressive Aphasia, historical and forecasted epidemiology as well as the Primary Progressive Aphasia market trends in the 7MM. Primary Progressive Aphasia Signs and symptoms The symptoms of the disease may include: 1.Speech problems may include ●difficulty naming objects ●difficulty forming words ●frequent pauses in speech ●slow speech ●difficulty comprehending speech ●problems with grammar

2. 2.Behavioral changes may include ●depression ●apathy ●anxiety ●agitation ●irritability ●as well as abnormal appetite ●lack of insight Primary Progressive Aphasia (PPA) Treatment Therapies Primary progressive aphasia that can't be cured, and there is no cure for it. However, some of the treatments that can help you improve or maintain your ability to communicate, and manage your physical fitness. Speech and language therapy is an option which can be considered best in case of above described symptoms. The Primary Progressive Aphasia market report 2030 provides Primary Progressive Aphasia treatment algorithms and therapies in the 7mm. Primary Progressive Aphasia Epidemiology Insights Primary Progressive Aphasia is caused by a loss of tissue (atrophy) in the area of the brain that is responsible for producing language. Primary Progressive Aphasia can be classified into three different types such as Progressive non-fluent aphasia, Semantic dementia and Logopenic progressive aphasia. In some cases, this loss of tissue is caused by genetic changes (mutations or pathogenic variants) in the GRN gene. In these cases, the disease is inherited in an autosomal dominant manner. Key Findings: ●According to a study, stated that no community-based estimates of the frequency of Primary Progressive Aphasia are available, but a rough estimate can be derived by considering that the etiology is often in the clinical spectrum related to frontotemporal lobar degeneration. Estimated prevalence of FTLD was in the range of 2.7–15.0 per 100,000. ●As per study, stated that a clinical diagnosis of Primary Progressive Aphasia was associated with frontotemporal lobar degeneration (FTLD) with TDP inclusions in 40.5%, FTLD-tau in 40.5%, and Alzheimer’s disease (AD) pathology in 19% of cases. The epidemiology section of the DelveInsight Primary Progressive Aphasia report also includes information on the diagnosed patient pool, trends, and assumptions used.

3. For each of the seven major countries, the Primary Progressive Aphasia epidemiology section provides information on historical and present Primary Progressive Aphasia patient pools, as well as predicted trends. Primary Progressive Aphasia Market Insights There are currently no effective drug intervention in the market for the treatment of primary progressive aphasia. A very important parameter for the primary progressive aphasia, it is in the knowledge that your brain diseases, for example Alzheimer's disease, FTLD-tau or FTLD-TDP- 43) is set to lead to a DAD because of the more effective treatment of PORRIDGE, is dependent on the individual level. Key Findings: ●The market size is expected to increase at a CAGR of XX% during the study period 2017-2030. By assessing the impact of current medicines on the market, unmet needs, drivers and barriers, and demand for better technologies, the Primary Progressive Aphasia market outlook report helps to establish a complete understanding of historic, present, and future Primary Progressive Aphasia market trends. According to DelveInsight, the Primary Progressive Aphasia market in 7MM is expected to change in the study period 2017-2030. Primary Progressive Aphasia Emerging Therapy Assessment The Primary Progressive Aphasia pipeline scenario seems very narrow with few products mainly for neurodegenerative disorders. Few of the drugs under development for Frontotemporal Dementia are AL001 (Alector), AADvac1 (Axon Neuroscience), etc. ●AL001 is Alector’s wholly-owned human monoclonal antibody designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease, and Parkinson’s disease. AL001 was discovered and engineered in collaborative effort between Alector and Adimab. ●AADvac1 is an active immunotherapy targeting pathological altered tau protein in Alzheimer's disease, which is a major component of neurofibrillary tangles (NFTS). AADvac1 is an active vaccine to be developed, to enable an immune response against the pathologically altered forms of tau protein. Designed by the Axon Neuroscience at the stage, and primary progressive non-fluent aphasia. The emerging therapy assessment segment of the Primary Progressive Aphasia report encloses a detailed analysis of Primary Progressive Aphasia marketed drugs and late-stage pipeline drugs.